Abstract 185P
Background
It has been proven that with tumor lesions of the organs of the biliopancreatoduodenal (BPDZ), tumor cells excessively release tumor necrosis factor (TNF-α) in the blood serum and determining their level can assess the activity of the tumor process and the effectiveness of the therapy. Among the causes of mechanical jaundice, the pancreatic head tumor prevailed - 36.1% of patients, in 27.7% of patient's cholestasis was due to a liver gate tumor, in 16.6% - a tumor of the terminal segment of the choledochus, in 13.8% - cancer of the Voter papilla, 5.5% - cancer of the common hepatic duct.
Methods
The study involved 32 patients treated at the General Surgery Department in Tashkent Medical Academy with mechanical jaundice (MJ) with malignant etiology after the application of per-cutaneous-transhepatic cholangiostomy (PTCH). The age of patients ranged from 30 to 74 years, averaging 53.7 ± 3.2 years. There were 19 women and 13 men. In order to remove TNF-α from the body, cholesorption was performed.
Results
The initial concentration of TNF-α in serum averaged 467.43 ± 12.36 (in the norm of 0-5.9 pg/ml). The use of cholesorption contributed to a sharp decrease in the concentration of TNF-α in serum and enhancement of its elimination from the bile. On the 3rd day of observation in the serum, there was a decrease in the concentration of TNF-α by 55.7%. The following days, the serum TNF-α concentration tended to increase and on the 6th day, it averaged 242.05 ± 15.6pg / ml. The next day, serum levels showed a gradual decrease in the concentration of TNF-α and on the 10th day of cholesorption averaged 89.46 ± 7.4-65.49 ± 8.95pg / ml, respectively. On the 14th day of cholesorption in comparison with the initial level, the concentration of TNF-α in the serum decreased 5.5 times.
Conclusions
Thus, the use of cholesorption in patients with MJ of tumor genesis contributes to ridding the body of the pro-inflammatory cytokine TNF-α. The determination of TNF-α in the bile increases the objectivity of the method in assessing the course of the main process and the treatment carried out for BPDZ tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - Clinical verification on the relationship between serum lipid metabolism and the immune microenvironment in breast cancer patients
Presenter: Wataru Goto
Session: Poster display session
Resources:
Abstract
42P - Genome wide copy number analysis of circulating tumour cells in breast cancer liver metastasis
Presenter: Saber Imani
Session: Poster display session
Resources:
Abstract
43P - A hotspot variants p.H1047R and p.H1047L in p110α/ΔNp63α complex affects structure, function and contributes to susceptibility metastatic breast cancer
Presenter: Zou Linglin
Session: Poster display session
Resources:
Abstract
44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
45P - The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location
Presenter: Hubert Beaumont
Session: Poster display session
Resources:
Abstract
46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics
Presenter: Aditia Romadhoni
Session: Poster display session
Resources:
Abstract
47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer
Presenter: MAYUKO MIKI
Session: Poster display session
Resources:
Abstract
48P - Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis
Presenter: Ahmad Murtadha
Session: Poster display session
Resources:
Abstract
49P - Biochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
50P - Prognostic factors of recurrence or distant metastasis in elderly breast cancer patients
Presenter: Seungju Lee
Session: Poster display session
Resources:
Abstract